Adial Pharmaceuticals, Inc. Number of Reportable Segments
Adial Pharmaceuticals, Inc. (ADIL) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-14
- 2025-09-30: Number of Reportable Segments 9 month 100.00%.
- 2025-06-30: Number of Reportable Segments 6 month 100.00%.
pure
| Period end | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month |
|---|---|---|
| 2025-09-30 | 100.00% 10-Q · filed 2025-11-13 | |
| 2025-06-30 | 100.00% 10-Q · filed 2025-08-13 |
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 12 month |
|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-08 | ||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |